Researchers showed that LGP2 binds viral RNA ends and recruits MDA5 molecules to form filament clusters that activate ...

九州大学は、極限環境がリボ核酸(RNA)の前生物化学に与える影響を調査し、「アデノシン一リン酸」(AMP)がRNA鎖へ繋がる重合反応を起こす証拠は発見できず、逆に多様な有機化合物へ分解・再編成されることを発見したと発表した。

2019年にスタートした本連載「Innovative Tech」は、世界中の幅広い分野から最先端の研究論文を独自視点で厳選、解説する。執筆は研究論文メディア「Seamless」（シームレス）を主宰し、日課として数多くの論文に目を通す山下氏が担当。イラストや漫画は、同メディア所属のアーティスト・おね氏が手掛けている。X：＠shiropen2 英ケンブリッジ大学などに所属する研究者らがScience誌 ...

Discover how circular RNA technology enhances gene expression by up to 50-fold in eye treatments, surpassing traditional ...

RIKEN researchers have discovered how an enzyme modifies gene expression by targeting certain stretches of messenger RNA ...

In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions ...

Researchers found that nonsense-mediated mRNA decay, via the UPF2 protein, is crucial for neuronal migration and cortical ...

Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 ...

Reduce amplification bias caused by variable miRNA abundance using automated PCR normalization for NEXTFLEX small RNA sequencing workflows.

Emerging modalities such as self-amplifying and circular RNA, expanding oncology and rare-disease applications, and scalable manufacturing are creating high-growth investment avenues, supported by ...

Four months after Avidity’s $11.4 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its ...

Ionis Pharmaceuticals is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The ...